“We are honored and excited that the ongoing progress of our scientific investigators and advisors showcases the differentiated benefits of Nano-Pulse Stimulation technology and helps clinicians envision the promise of an elegant solution that clears hard-to-treat skin lesions for their patients,” said
To date, close to 700 patients and more than 3,600 lesions have been successfully treated in clinical studies using NPS technology delivered by the CellFX System. These studies include a spectrum of common skin lesions, notably Sebaceous Hyperplasia, non-genital Warts, Seborrheic Keratoses, Acne,
The company recently announced its quarterly progress on its clinical and regulatory objectives. “The clinical evidence supporting the utility of NPS technology delivered by the CellFX System continues to grow as a result of the investigational use by a broad group of aesthetic dermatology key opinion leaders,” said
Virtual Podium Presentation
“Nano-Pulse Stimulation Technology” by Dr.
About Pulse Biosciences®
Caution: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation technology are for investigational use only.
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to Pulse Biosciences’ expectations regarding regulatory clearance and the timing of FDA and other regulatory filings or approvals, including meetings with FDA and the ability of the Company to successfully complete a 510(k) submission for the CellFX System or for a specific indication for the treatment of sebaceous hyperplasia (SH) lesions, the ability of the Company to prepare and provide data to FDA and other regulatory bodies, NPS technology including the effectiveness of such technology and the effectiveness of related clinical studies in predicting outcomes resulting from the use of NPS technology, the CellFX System including the benefits of the CellFX System and commercialization of the CellFX System, current and planned future clinical studies and the ability of the Company to execute such studies and results of any such studies, other matters related to its pipeline of product candidates, the Company’s market opportunity and commercialization plans, including the market for the treatment of SH, future financial performance, the impact of COVID-19 and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the
Nadine D. Tosk